"We Envision Growth Strategies Most Suited
to Your Business"
The anti-inflammatory biologics market size touched USD 93.13 billion in 2022 and is predicted to reach USD 93.32 billion in 2023. The market is anticipated to touch USD 139.80 billion by 2030, recording a CAGR of 5.9% over 2023-2030.
Fortune Business Insights™ presents this information in its latest report titled “Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030”.
Anti-inflammatory biologics is one of the most emerging treatments for treating autoimmune disorders. Inflammatory diseases, such as ulcerative colitis, psoriasis, inflammatory bowel diseases, and rheumatoid arthritis are growing at a worrying rate across the world, which is predicted to fuel the market growth.
COVID-19 Pandemic Accelerated Market Growth Due to Robust Sales of Biologics
The COVID-19 pandemic improved the market’s growth as several people, particularly those suffering from a severe case of COVID-19, suffered from acute inflammation. This scenario increased the need for repurposing anti-inflammatory medicines, which further boosted the market’s growth during this period.
Incyte Declared New Results from Clinical Trials Analyzing Its New Cream
Incyte declared new 104-week results from the important Phase 3 TRuE-V clinical trial program analyzing the effectiveness of its Opzelura (ruxolitinib) cream. The cream is utilized in patients falling in the age category of 12 years and above and suffering from nonsegmental vitiligo at the 2023 American Academy of Dermatology (AAD) Annual Meeting.
Growing Incidence of Inflammatory Disorders to Augment Market Progress
The prevalence of autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and ankylosing spondylitis is rising at a worrying rate, especially among the younger population. This factor has compelled market players to introduce novel anti-inflammatory biologics to treat these ailments and expand their customer base. These aspects are expected to support the market development.
However, many patients do not opt for biologics as the first line of treatment, which can restrict the market’s growth.
AbbVie Dominated Market Due to Strong Product Portfolio
AbbVie held a dominant position in the market as the company has a strong and vast product portfolio. Various factors, such as high investments in research & development, robust sales of Humira, and great market presence are helping the company dominate this market.
Notable Industry Development:
To get a detailed report summary and research scope of this market, click here:
List of the Companies Profiled in the Report:
Further Report Findings
Table of Segmentation
CAGR of 5.9% from 2023-2030
Value (USD billion)
By Drug Class
By Route of Administration
By Distribution Channel